

Serial No.: 10/620,404

Applicant: James M. Ntambi

Date of Office Action: August 6, 2009

Date of Response: February 8, 2010

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the above identified application.

Listing of Claims:

1.-5. (Canceled)

6. (Withdrawn) A method of increasing insulin sensitivity in a human or non-human subject, the method comprising the steps of:

administering an agent for reducing stearoyl-CoA desaturase 1 (SCD1) activity in the human or non-human subject to increase insulin sensitivity; and

measuring insulin sensitivity and observing an increase in insulin sensitivity following a reduction in SCD1 activity, wherein the agent is a polyunsaturated fatty acid selected from the group consisting of dodecahexaenoic acid and arachidonic acid.

7. (Previously presented) A method of increasing insulin sensitivity in a human or non-human subject, the method comprising the steps of:

administering an agent for reducing stearoyl-CoA desaturase 1 (SCD1) activity in the human or non-human subject to increase insulin sensitivity; and

measuring insulin sensitivity and observing an increase in insulin sensitivity following a reduction in SCD1 activity, wherein the agent is an antisense oligonucleotide for SCD1.

Serial No.: 10/620,404

Applicant: James M. Ntambi

Date of Office Action: August 6, 2009

Date of Response: February 8, 2010

8. (Withdrawn) A method of increasing insulin sensitivity in a human or non-human subject, the method comprising the steps of:

administering an agent for reducing stearoyl-CoA desaturase 1 (SCD1) activity in the human or non-human subject to increase insulin sensitivity; and

measuring insulin sensitivity and observing an increase in insulin sensitivity following a reduction in SCD1 activity, wherein the agent reduces SCD1 activity by inhibiting enzymatic activity of SCD1.

9. (Withdrawn) The method of claim 8, wherein the agent is an SCD1 inhibitor.

10. (Withdrawn) The method of claim 9, wherein the agent that inhibits enzymatic activity of SCD1 is an anti-SCD1 antibody.

11. (Withdrawn) The method of claim 8, wherein the agent that inhibits SCD1 enzymatic activity inhibits a protein selected from the group consisting of a cytochrome b₅ protein, a NADH-cytochrome b₅ reductase protein, and a terminal cyanide-sensitive desaturase protein.

12.-13. (Canceled)